^
Association details:
| Biomarker: | MYD88 mutation + PRDM15 expression |
|---|---|
| Cancer: | Waldenstrom Macroglobulinemia |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1538 Identification of Robust Predictors for Ibrutinib Response By Multi-Omic Genomics in MYD88 Mutated Waldenstrom’s Macroglobulinemia
Published date:
11/03/2022
Excerpt:
Attainment of a major response at 6 months was strongly associated with expression of WNK2 (p=0.0043), as well as DUSP22, GPER1, TNIK and PRDM15 (all p<0.0001). Long-term PFS correlated with attainment of major response at 6 months for these biomarkers.... By use of comprehensive multi-omic genomics, we identified robust biomarkers for clinical investigation to predict ibrutinib major response at 6 months and long term PFS in MYD88 mutated WM patients that included many regulators of ERK1/2 signaling such as WNK2, GPER1, DUSP22, TNIK and PRDM15.
DOI:
https://doi.org/10.1182/blood-2022-170254
